Details of how to report adverse events are available at the bottom of the page.
For full information on a Roche medicine, please see the relevant Summary of Product Characteristics.
This is a promotional website intended for UK healthcare professionals, designed, built and funded by Roche Products Ltd.
Discover Insights from DLBCL Experts on Recent Updates from 1L and 3L+ Registration Studies
Professor Graham Collins discusses the POLARIX five-year follow-up analysis of POLIVY®▼ (polatuzumab vedotin) in combination with R-CHP in 1L DLBCL, while Professor Andy Davies gives his opinion on the 3-year follow-up data from the NP30179 Phase II expansion study of COLUMVI®▼ (glofitamab) monotherapy in 3L+ DLBCL.
Prescribing Information
1L: Highlights from the POLARIX 5-Year Follow-Up Analysis
POLIVY in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Professor Graham Collins
3L+: Highlights from the NP30179 Phase II Expansion 3-Year Follow-Up Analysis
COLUMVI as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
Professor Andy Davies
All data included on this page fall within the relevant product licence for Roche products. For product information, please refer to the relevant Summary of Product Characteristics. Information on this page includes non-Roche medicines that are not licensed in the UK, or being used outside of their licensed indications. Should you require further information on a molecule that is not produced by Roche Products Ltd, please contact the relevant manufacturer.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Adverse reactions should be reported by brand name and batch number.
DLBCL; diffuse large B-cell lymphoma. 1L; first line. 3L+; third line and beyond. R-CHP; rituximab, cyclophosphamide, doxorubicin, and prednisone.